AI制药第一股上市，我识破了股市里的假象

Core Viewpoint - The listing of Insilico Medicine on the Hong Kong Stock Exchange marks it as the first AI pharmaceutical stock in the market, raising questions about the potential for stock price increases driven by hype around AI in pharmaceuticals [1] Group 1: Market Reactions and Investor Behavior - Many investors tend to react impulsively to major news, believing that significant announcements will lead to stock price increases, but often the reality is different [2] - A previous case involving an AI company showed that despite initial stock price increases following a financing announcement, the stock eventually declined due to lack of institutional participation [3] Group 2: Importance of Institutional Participation - The concept of "institutional inventory" is crucial; if institutional investors are not actively participating, any price increase may be unsustainable and driven by smaller investors [3][6] - Historical examples illustrate that stocks with active institutional participation tend to have more reliable price movements, while those without such support may experience volatility without real backing [4][6] Group 3: Strategies for Ordinary Investors - Ordinary investors often make mistakes by following market sentiment rather than focusing on actual trading behaviors and institutional involvement [8] - It is recommended that investors prioritize understanding institutional participation over reacting to news or price movements, as this can help avoid pitfalls in trading [8][9] Group 4: Long-term Investment Perspective - A focus on long-term institutional interest is essential for assessing the potential of stocks like Insilico Medicine, rather than making decisions based solely on short-term market reactions [8][9] - The stability and growth of a stock are more likely to be influenced by sustained institutional investment rather than temporary market hype [9]